Tilray (TLRY.US) stock surged 50% today extending yesterday massive gains as cannabis sector has become a new area of interest of reddit traders. One post on WallStreetBets, which users were responsible for the recent rally in GameStop Corp (GME.US) and AMC Entertainment (AMC.US), regarding cannabis stocks was liked by around 10,000 other users in just twelve hours and Tilray shares soared 21%.
Yesterday Tilray stock jumped nearly 40 % after the company signed a deal with Grow Pharma to import and distribute its medical cannabis products to British patients. Prescriptions will need to be obtained through the country’s National Health Service or from a private-practice doctor. Tilray expects its cannabis products to be available in the UK by March. "Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients' quality of life," said Sascha Mielcarek, managing director of Tilray Europe.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
Tilray (TLRY.US) stock surged this week, however buyers failed to break above the major resistance at $67.21 and price pulled back to the $51.40 handle that is the key support for now. As long as the price sits above it, the upward move looks to be more probable. Only breaking below this hurdle, may pave the way for a bigger downward correction towards $23.18. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
